Cargando…

Controversies in the treatment of postmenopausal osteoporosis: How long to treat with bisphosphonates?

Osteoporosis is a systemic skeletal disease characterized by reduced bone mass and deterioration of bone tissue microarchitecture leading to an increased risk of fractures. Fragility fractures, especially hip fractures, are associated with a significant reduction in the physical function and quality...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bandeira, Francisco, Dantas, Wesdrey, Bilezikian, John P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Endocrinologia e Metabologia 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10522084/ https://www.ncbi.nlm.nih.gov/pubmed/32725062 http://dx.doi.org/10.20945/2359-3997000000275

Ejemplares similares

Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis
por: Pazianas, Michael, et al.
Publicado: (2010)

Intravenous bisphosphonates for postmenopausal osteoporosis
por: Mottaghi, Peyman
Publicado: (2010)

Long-term consequences of osteoporosis therapy with denosumab
por: Bandeira, Francisco, et al.
Publicado: (2022)

Patient preference in the management of postmenopausal osteoporosis with bisphosphonates
por: Reginster, Jean-Yves, et al.
Publicado: (2006)

Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosis
por: Bauss, Frieder, et al.
Publicado: (2006)

Male osteoporosis
por: Bandeira, Leonardo, et al.
Publicado: (2022)

Optimizing dosing frequencies for bisphosphonates in the management of postmenopausal osteoporosis: patient considerations
por: Sunyecz, John
Publicado: (2008)

Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis
por: Wu, Jiaqi, et al.
Publicado: (2018)

Bisphosphonates in the management of postmenopausal osteoporosis – optimizing efficacy in clinical practice
por: Bock, Oliver, et al.
Publicado: (2008)

The efficacy and safety of denosumab in postmenopausal women with osteoporosis previously treated with bisphosphonates: A review
por: Zhu, Yilin, et al.
Publicado: (2019)

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates
por: Miller, P. D., et al.
Publicado: (2016)

Adiponectin as a Biomarker of Osteoporosis in Postmenopausal Women: Controversies
por: Lubkowska, Anna, et al.
Publicado: (2014)

Trajectories of Bone Remodeling Markers and Bone Mineral Density during Treatment with Strontium Ranelate in Postmenopausal Women Previously Treated with Bisphosphonates
por: Lima, Helisane, et al.
Publicado: (2014)

Long-Term Treatment of Postmenopausal Osteoporosis
por: Brown, Jacques P.
Publicado: (2021)

Bone metabolism genes variation and response to bisphosphonate treatment in women with postmenopausal osteoporosis
por: Marozik, Pavel, et al.
Publicado: (2019)

Antiresorptive Drugs Beyond Bisphosphonates and Selective Oestrogen Receptor Modulators for the Management of Postmenopausal Osteoporosis
por: Reginster, J. Y., et al.
Publicado: (2014)

Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates
por: Petranova, T., et al.
Publicado: (2017)

Differences between the bisphosphonates for the prevention and treatment of osteoporosis
por: Grey, Andrew, et al.
Publicado: (2006)

Novel formulations of oral bisphosphonates in the treatment of osteoporosis
por: Fuggle, Nicholas, et al.
Publicado: (2022)

Long-term use of bisphosphonates in osteoporosis
por: Sadat-Ali, Mir, et al.
Publicado: (2017)

Long-term use of bisphosphonates in osteoporosis
por: Alwahhabi, Basmah K., et al.
Publicado: (2017)

Bisphosphonates adherence for treatment of osteoporosis
por: Vieira, Helena Parente, et al.
Publicado: (2013)

Treatment options for postmenopausal osteoporosis
por: Walsh, Garry M
Publicado: (2012)

Impact of the Training on the Compliance and Persistence of Weekly Bisphosphonate Treatment in Postmenopausal Osteoporosis: A Randomized Controlled Study
por: Tüzün, Şansın, et al.
Publicado: (2013)

Longitudinal Changes of Circulating miRNAs During Bisphosphonate and Teriparatide Treatment in an Animal Model of Postmenopausal Osteoporosis
por: Weigl, Moritz, et al.
Publicado: (2021)

Role of Bisphosphonates in Postmenopausal Women with Osteoporosis to Prevent Future Fractures: A Literature Review
por: Imam, Bashir, et al.
Publicado: (2019)

The Role of Bisphosphonates Prior to Denosumab Treatment on Rebound Fractures: A Mini Review
por: Inojosa, Arthur Costa, et al.
Publicado: (2022)

Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study
por: Jakob, F, et al.
Publicado: (2012)

Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study
por: Jakob, F, et al.
Publicado: (2012)

Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis
por: Lewiecki, E Michael
Publicado: (2009)

OR03-1 The Effect of Abaloparatide on Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis and Osteoarthritis
por: Lane, Nancy, et al.
Publicado: (2019)

Physicians’ perspectives on the treatment of osteoporosis patients with bisphosphonates
por: Gu, Tao, et al.
Publicado: (2016)

Anabolic treatments for osteoporosis in postmenopausal women
por: Hassan, Neelam, et al.
Publicado: (2021)

Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis
por: Karlsson, L., et al.
Publicado: (2015)

Botanicals in Postmenopausal Osteoporosis
por: Słupski, Wojciech, et al.
Publicado: (2021)

Additive effects of eldecalcitol in poorly responding long-term bisphosphonate treatment for osteoporosis
por: Kamimura, Mikio, et al.
Publicado: (2019)

Quarterly intravenous injection of ibandronate to treat osteoporosis in postmenopausal women
por: Sambrook, Philip
Publicado: (2007)

Long-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: an update
por: Messalli, Enrico M, et al.
Publicado: (2010)

Long-term efficacy, safety, and patient acceptability of ibandronate in the treatment of postmenopausal osteoporosis
por: Inderjeeth, Charles A, et al.
Publicado: (2014)

GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab
por: Hadji, P., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_3ohre7nlqvk8tl1sa1a8a38k2p